Skip to content

Released Nov 4, 2025, before the open

10-Q filed Nov 4, 2025, 35 days after period end · 0001193125-25-263670

Q3 2025 · 10-Q
Revenue$205.63M+4.6% vs Q3 2024+1.2% vs Q2 2025
Net Income-$22.80MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.57N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$148,523,000+10.0%
Operating Income-$17,046,000N/M
Operating Cash Flowderived$12,402,000+6.3%
Free Cash Flowderived$2,498,000−60.7%
Margins · derived
Gross margin72.2%+3.5 pt vs Q3 2024
Operating margin-8.3%+1.3 pt vs Q3 2024
Net margin-11.1%+2.8 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$205.63M$196.61M$184.01M$114.00M
Net Income-$22.80M-$27.39M-$28.86M-$10.72M
EPS Diluted-$0.57-$0.71-$0.77-$0.53

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR